Misplaced Pages

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Dapagliflozin/saxagliptin/metformin" – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message) This article may contain excessive or inappropriate references to self-published sources. Please help improve it by removing references to unreliable sources where they are used inappropriately. (July 2020) (Learn how and when to remove this message) (Learn how and when to remove this message)

Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca.

The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite.

Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca.

Medical uses

In the United States, dapagliflozin/saxagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes:

• to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.
• when already being treated with metformin and saxagliptin and dapagliflozin.

References

1. ^ "Qternmet XR- dapagliflozin saxagliptin and metformin hydrochloride tablet, film coated". DailyMed. 24 January 2020. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
2. ^ "Qtrilmet EPAR". European Medicines Agency (EMA). 16 September 2019. Archived from the original on 29 December 2019. Retrieved 14 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
3. "AstraZeneca Medications". AstraZeneca US. April 2020. Archived from the original on 4 May 2020. Retrieved 30 March 2020.
4. "Drug Approval Package: Qternmet XR". U.S. Food and Drug Administration (FDA). 27 January 2020. Archived from the original on 17 February 2020. Retrieved 14 July 2020.
5. "Qternmet XR approved in the US for the treatment of type-2 diabetes". AstraZeneca (Press release). 3 May 2019. Archived from the original on 16 July 2020. Retrieved 14 July 2020.
6. "Qtrilment" (PDF). European Medicines Agency. 9 October 2020. Archived (PDF) from the original on 30 March 2021. Retrieved 30 March 2021.
7. "Bristol-Meyers Squibb Company, et al.; Withdrawal of Approval of 19 New Drug Applications". Federal Register. 16 March 2021. Archived from the original on 30 March 2021. Retrieved 30 March 2021.

• Medicine

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs developed by AstraZeneca
• Biguanides
• Chloroarenes
• Combination diabetes drugs
• Glucosides
• Guanidines
• Phenol ethers
• SGLT2 inhibitors
• Gastrointestinal system drug stubs